The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis

Mazen Elyan, Muhammad Asim Khan

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-α inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.

Original languageEnglish (US)
Pages (from-to)255-259
Number of pages5
JournalCurrent Rheumatology Reports
Volume8
Issue number4
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Ankylosing Spondylitis
Anti-Inflammatory Agents
Sacroiliac Joint
Cyclooxygenase 2 Inhibitors
Rheumatic Diseases
Spine
Tumor Necrosis Factor-alpha
Clinical Trials
Safety
Drug Therapy
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis. / Elyan, Mazen; Khan, Muhammad Asim.

In: Current Rheumatology Reports, Vol. 8, No. 4, 08.2006, p. 255-259.

Research output: Contribution to journalReview article

@article{fea61ec865a54e6f9d1eb4a32a079b9c,
title = "The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis",
abstract = "Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-α inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.",
author = "Mazen Elyan and Khan, {Muhammad Asim}",
year = "2006",
month = "8",
doi = "10.1007/s11926-006-0005-7",
language = "English (US)",
volume = "8",
pages = "255--259",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitis

AU - Elyan, Mazen

AU - Khan, Muhammad Asim

PY - 2006/8

Y1 - 2006/8

N2 - Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-α inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.

AB - Ankylosing spondylitis (AS) is a chronic systemic rheumatic disease that primarily affects the sacroiliac joints and spine. Even with the development of tumor necrosis factor-α inhibitors, which have revolutionized the treatment of this disease, the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, and a life-long exercise program still form the first step in its management. Multiple clinical trials have addressed the efficacy and safety of both nonselective and selective NSAIDs. Gastrointestinal toxicity remains their major side effect, with increased concern about the potential of cardiovascular toxicity, especially with the selective cyclooxygenase-2 inhibitors. A specific set of recommendations has been proposed for the management of AS.

UR - http://www.scopus.com/inward/record.url?scp=33748426134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748426134&partnerID=8YFLogxK

U2 - 10.1007/s11926-006-0005-7

DO - 10.1007/s11926-006-0005-7

M3 - Review article

C2 - 16859622

AN - SCOPUS:33748426134

VL - 8

SP - 255

EP - 259

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 4

ER -